63 related articles for article (PubMed ID: 17094272)
1. Learning a predictive model for growth inhibition from the NCI DTP human tumor cell line screening data: does gene expression make a difference?
Richter L; Rückert U; Kramer S
Pac Symp Biocomput; 2006; ():596-607. PubMed ID: 17094272
[TBL] [Abstract][Full Text] [Related]
2. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
Marx KA; O'Neil P; Hoffman P; Ujwal ML
J Chem Inf Comput Sci; 2003; 43(5):1652-67. PubMed ID: 14502500
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data.
Blower PE; Yang C; Fligner MA; Verducci JS; Yu L; Richman S; Weinstein JN
Pharmacogenomics J; 2002; 2(4):259-71. PubMed ID: 12196914
[TBL] [Abstract][Full Text] [Related]
4. Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
Wallqvist A; Connelly J; Sausville EA; Covell DG; Monks A
Mol Pharmacol; 2006 Mar; 69(3):737-48. PubMed ID: 16332985
[TBL] [Abstract][Full Text] [Related]
5. Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors.
Jang IS; Dienstmann R; Margolin AA; Guinney J
Pac Symp Biocomput; 2015; 20():32-43. PubMed ID: 25592566
[TBL] [Abstract][Full Text] [Related]
6. Update on NCI in vitro drug screen utilities.
Holbeck SL
Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
[TBL] [Abstract][Full Text] [Related]
7. Anticancer SAR models for MCF-7 and MDA-MB-231 breast cell lines.
Qamar S; Carrasquer CA; Cunningham SL; Cunningham AR
Anticancer Res; 2011 Oct; 31(10):3247-52. PubMed ID: 21965732
[TBL] [Abstract][Full Text] [Related]
8. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
9. Psoralen analogues: synthesis, inhibitory activity of growth of human tumor cell lines and computational studies.
Oliveira AM; Raposo MM; Oliveira-Campos AM; Machado AE; Puapairoj P; Pedro M; Nascimento MS; Portela C; Afonso C; Pinto M
Eur J Med Chem; 2006 Mar; 41(3):367-72. PubMed ID: 16439037
[TBL] [Abstract][Full Text] [Related]
10. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer.
Hsu YC; Yuan S; Chen HY; Yu SL; Liu CH; Hsu PY; Wu G; Lin CH; Chang GC; Li KC; Yang PC
Clin Cancer Res; 2009 Dec; 15(23):7309-15. PubMed ID: 19920108
[TBL] [Abstract][Full Text] [Related]
11. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
Yamori T
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939
[TBL] [Abstract][Full Text] [Related]
12. A multivariate analysis approach to the integration of proteomic and gene expression data.
Fagan A; Culhane AC; Higgins DG
Proteomics; 2007 Jun; 7(13):2162-71. PubMed ID: 17549791
[TBL] [Abstract][Full Text] [Related]
13. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
14. Class prediction from time series gene expression profiles using dynamical systems kernels.
Borgwardt KM; Vishwanathan SV; Kriegel HP
Pac Symp Biocomput; 2006; ():547-58. PubMed ID: 17094268
[TBL] [Abstract][Full Text] [Related]
15. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
17. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.
Dangles-Marie V; Pocard M; Richon S; Weiswald LB; Assayag F; Saulnier P; Judde JG; Janneau JL; Auger N; Validire P; Dutrillaux B; Praz F; Bellet D; Poupon MF
Cancer Res; 2007 Jan; 67(1):398-407. PubMed ID: 17210723
[TBL] [Abstract][Full Text] [Related]
18. QSAR modeling, synthesis and bioassay of diverse leukemia RPMI-8226 cell line active agents.
Katritzky AR; Girgis AS; Slavov S; Tala SR; Stoyanova-Slavova I
Eur J Med Chem; 2010 Nov; 45(11):5183-99. PubMed ID: 20843586
[TBL] [Abstract][Full Text] [Related]
19. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
20. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
